Verition Fund Management
RGLS

Verition Fund Management’s Regulus Therapeutics RGLS Stock Holding History

Verition Fund Management’s Portfolio RGLS Stock Details RGLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-1,321
Closed -$10K – 1320
2019
Q3 		$10K Hold
1,321
– – ﹤0.01% 1010
2019
Q2 		$17K Buy
+1,321
New +$15.2K ﹤0.01% 1030

Other funds holding RGLS

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
CH
CVI Holdings Wilmington, Delaware $116M AUM 5.68% 1-Year Est. Return
Rockefeller Capital Management
Rockefeller Capital Management New York $56.4B AUM 24.96% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WS
Wedbush Securities Los Angeles, California $3.43B AUM 24.13% 1-Year Est. Return

Verition Fund Management's RGLS Position: Q4 2019 in Review

Verition Fund Management sold out of Regulus Therapeutics (RGLS) in Q4 2019, closing a stake of 1,321 shares — an estimated $10K sold.

Verition Fund Management first reported a position in RGLS in Q2 2019 and held it in 2 quarters. The position peaked at $17K in Q2 2019. 24 funds tracked by Wall St. Rank hold RGLS as of Q4 2019.

  • Verition Fund Management reported no remaining Regulus Therapeutics position as of Q4 2019 after selling out during the quarter.
  • Verition Fund Management sold 1,321 Regulus Therapeutics shares in Q4 2019, an estimated $10K.
  • Verition Fund Management first reported a position in Regulus Therapeutics in Q2 2019 and held it in 2 quarters.
  • Verition Fund Management's Regulus Therapeutics position peaked at $17K in Q2 2019.
  • 24 funds tracked by Wall St. Rank held Regulus Therapeutics as of Q4 2019.

Based on Verition Fund Management's 13F filing for Q4 2019, filed 14 Feb 2020.